CY1111825T1 - Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη - Google Patents

Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη

Info

Publication number
CY1111825T1
CY1111825T1 CY20111100260T CY111100260T CY1111825T1 CY 1111825 T1 CY1111825 T1 CY 1111825T1 CY 20111100260 T CY20111100260 T CY 20111100260T CY 111100260 T CY111100260 T CY 111100260T CY 1111825 T1 CY1111825 T1 CY 1111825T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
optional component
compositions including
coating
active agent
Prior art date
Application number
CY20111100260T
Other languages
English (en)
Inventor
Benjamin Oshlack
Hua-Pin Huang
Rampurna Gullapalli
Meredith Machonis
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1111825T1 publication Critical patent/CY1111825T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Φαρμακευτικές συνθέσεις που περιέχουν θεραπευτικά δραστικό παράγοντα, επίχρισμα εμπόδιο στη διάχυση και επίχρισμα το οποίο περιλαμβάνει υδρόφοβο υλικό.
CY20111100260T 2002-08-15 2011-03-04 Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη CY1111825T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40371102P 2002-08-15 2002-08-15
EP07121574A EP1894562B1 (en) 2002-08-15 2003-08-15 Pharmaceutical compositions comprising an opioid antagonist

Publications (1)

Publication Number Publication Date
CY1111825T1 true CY1111825T1 (el) 2015-10-07

Family

ID=34078931

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20111100260T CY1111825T1 (el) 2002-08-15 2011-03-04 Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη
CY20111100311T CY1111821T1 (el) 2002-08-15 2011-03-22 Φαρμακευτικες συνθeσεις οι οποιες περιλαμβανουν ενα οπιουχο αναλγητικο

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100311T CY1111821T1 (el) 2002-08-15 2011-03-22 Φαρμακευτικες συνθeσεις οι οποιες περιλαμβανουν ενα οπιουχο αναλγητικο

Country Status (19)

Country Link
US (2) US20050266072A1 (el)
EP (2) EP1894562B1 (el)
JP (1) JP4790415B2 (el)
KR (1) KR20050086409A (el)
CN (1) CN1674873A (el)
AT (2) ATE493115T1 (el)
BR (1) BR0313627A (el)
CA (1) CA2495564A1 (el)
CY (2) CY1111825T1 (el)
DE (2) DE60335557D1 (el)
DK (2) DK1894562T3 (el)
ES (2) ES2358151T3 (el)
HK (1) HK1088211A1 (el)
IL (1) IL166561A0 (el)
MX (1) MXPA05001826A (el)
NZ (1) NZ537763A (el)
PT (2) PT1542658E (el)
SI (2) SI1894562T1 (el)
WO (1) WO2005007135A1 (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
IL149352A0 (en) 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
PT2283842E (pt) 2000-02-08 2015-07-01 Euro Celtique Sa Formulações orais de agonistas de opióides resistentes a adulteração
EP2295042A1 (en) 2000-10-30 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
WO2006119389A2 (en) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Quinine-containing controlled-release formulations
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
US20080119501A1 (en) * 2006-04-28 2008-05-22 Hein William A Immediate release oxymorphone compositions and methods of using same
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
HUE032156T2 (en) * 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
US7674479B2 (en) 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
DE602007005653D1 (de) * 2006-08-04 2010-05-12 Ethypharm Sa Mehrschichtige im mund zerfallende tablette
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
CA3066426A1 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
EP2976082A4 (en) 2013-03-15 2016-05-11 Inspirion Delivery Technologies Llc MISS-INFANT COMPOSITIONS AND METHODS OF USE
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
CN111836618A (zh) * 2018-02-08 2020-10-27 景凱生物科技股份有限公司 类阿片受体拮抗剂的固体剂型用的医药剂型
WO2022076470A1 (en) * 2020-10-06 2022-04-14 Sorrento Therapeutics, Inc. Oral delayed burst formulation of low-dose naltrexone or naloxone used for|treating fibromyalgia and long covid
EP4176724A1 (en) 2021-11-09 2023-05-10 Universität Hohenheim Use of an oleogel as a layer or coating

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1685839B8 (en) * 1997-12-22 2013-06-26 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
PT2283842E (pt) 2000-02-08 2015-07-01 Euro Celtique Sa Formulações orais de agonistas de opióides resistentes a adulteração
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2004515455A (ja) * 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド オピオイドアンタゴニスト組成物および投薬形態
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
RU2004106619A (ru) * 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
KR20040060917A (ko) * 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
JP4683842B2 (ja) * 2002-03-14 2011-05-18 ユーロ−セルティーク エス．エイ． 塩酸ナルトレキソン組成物
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
WO2004071423A2 (en) * 2003-02-05 2004-08-26 Euro-Celtique S.A. Methods of administering opioid antagonists and compositions thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products

Also Published As

Publication number Publication date
DK1542658T3 (da) 2011-04-04
EP1894562B1 (en) 2010-12-15
ES2358151T3 (es) 2011-05-06
HK1088211A1 (en) 2006-11-03
EP1542658A4 (en) 2006-04-05
CY1111821T1 (el) 2015-10-07
SI1894562T1 (sl) 2011-04-29
ES2358896T3 (es) 2011-05-16
DE60335426D1 (de) 2011-01-27
IL166561A0 (en) 2006-01-15
ATE491439T1 (de) 2011-01-15
NZ537763A (en) 2006-08-31
DE60335557D1 (de) 2011-02-10
EP1542658B1 (en) 2010-12-29
CA2495564A1 (en) 2005-01-27
ATE493115T1 (de) 2011-01-15
JP2006514988A (ja) 2006-05-18
SI1542658T1 (sl) 2011-04-29
PT1542658E (pt) 2011-02-03
CN1674873A (zh) 2005-09-28
WO2005007135A1 (en) 2005-01-27
DK1894562T3 (da) 2011-03-28
MXPA05001826A (es) 2005-04-19
JP4790415B2 (ja) 2011-10-12
PT1894562E (pt) 2011-01-14
KR20050086409A (ko) 2005-08-30
EP1542658A1 (en) 2005-06-22
US20160317456A1 (en) 2016-11-03
BR0313627A (pt) 2005-06-21
EP1894562A1 (en) 2008-03-05
US20050266072A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
CY1111825T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη
BR0207025B1 (pt) derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo.
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
MA26033A1 (fr) Agent active de livraison aerosol
MY141815A (en) Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
DE60044041D1 (de) Exendine zur Glucagon Suppression
HRP20041152B1 (en) Pharmaceutical formulations
ATE416771T1 (de) N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung
ITTO20010005A1 (it) Formulazione farmaceutica.
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
ATE469910T1 (de) Azithromycinmonohydrat
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE60210784D1 (de) Orale antidiabetische wirkstoffe
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
ATE326968T1 (de) Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer
ATE285753T1 (de) Lysin enthaltende kautablette
AU2003213997A1 (en) Biologically active copper-organic agents
ITMI20021725A1 (it) Composizioni farmaceutiche ad attivita' antibiotica.
NO20016147L (no) Biologiske aktive materialer
ITTO20000385A0 (it) Composizione pesticida.
TR199901017A3 (tr) Böcek ilaci terkibi.
DE60230292D1 (de) Aktivsauerstoff erzeugendes material
DE60129123D1 (de) BIOLOGISCH AKTIVE 4H-BENZOi1,4öOXAZIN-3-ONE
TR199901165A3 (tr) Piretroid bilesimi ve salgin hastaliklari için bunu içeren bilesikler.
DE50304615D1 (de) Dosieraerosole mit lecithin als oberflächenaktiver substanz